– USA, PA – Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the appointment of Tomas Heyman to its Board of Directors as a new member.
“We are pleased to welcome Tom to the Optinose Board of Directors,” said Boar Chairman, Joe Scodari. “His extraordinary experience in business development, and more broadly as a leader in the pharmaceutical industry, will make him a valuable addition to our Board of Directors.”
In addition, the Company also announced that Bill Doyle, who has served on the Board of Directors since 2010, and previously as a member of the OptiNose AS Board of Directors from 2004 to 2010, intends to resign on December 11, 2020.
“On behalf of Optinose I would like to thank Bill for his significant contributions as a member of our Board,” commented Mr. Scodari. “Bill was instrumental in bringing about the significant change in strategic direction for Optinose that led to the development of two FDA-approved products using its proprietary Exhalation Delivery System, and in building an organization focused on serving the needs of patients cared for by ear, nose and throat and allergy specialists.”
“It has been a privilege to work with the Optinose founders and management to develop their Exhalation Delivery System and to commercialize the XHANCE therapy,” said Bill Doyle. “I am highly confident in the efficacy of XHANCE and that there is a tremendous opportunity ahead for Optinose to reach the millions of new patients who can benefit from XHANCE treatment. I congratulate Tom Heyman for joining the Optinose board and look forward to providing continued assistance in a non-board capacity.”
About Tomas Heyman
Tom has a long-standing track record of leadership and management in the biopharmaceutical industry, with extensive experience in business development and venture capital. During his thirty-seven-year career with Johnson & Johnson, he held a diverse range of leadership roles across legal, R&D, business development, general corporate management, and equity investments. Most recently, he served as president of JJDC, the venture capital group within Johnson & Johnson, where he managed approximately $1.5 billion of capital and oversaw investments in more than 120 companies.
Prior to leading JJDC, he led business development for Johnson & Johnson’s pharmaceutical group, Janssen, for twenty-three years. Under his leadership the group completed hundreds of licensing and M&A transactions including the acquisitions of Centocor, Tibotec, Cougar Pharmaceuticals, and Aragon Pharmaceuticals.
In addition, he currently serves on the Board of Directors for Akero Therapeutics.
Tom graduated as Master of Law from the K.U. Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in business management at the University of Antwerp in Belgium.
About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat and allergy specialists.
For more information : https://www.optinose.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.